Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

Inclusion Criteria:

- Patients with biopsy proven (completed and/or reviewed at MSK) adenocarcinoma of the
prostate, who will undergo external beam radiotherapy using conventional fractionation
IGRT including moderate hypofractionated radiation, low rate brachytherapy alone,
brachytherapy (either high dose or low dose) combined with supplemental image guided
radiation (including IGRT, EBRT, and SBRT), SBRT, or proton radiotherapy.

- Age ≥ 18 years old

- Baseline MP-MRI, which is obtained at MSKCC Main Campus on the 3-Tesla Philips MRI
unit as part of the standard (clinical) staging assessment demonstrates at least one
dominant or visible lesion which measures > 0.5 cm in maximum axial diameter as
assessed on T2-weighted images.

- No prior history of androgen deprivation therapy within the last month. However
patients who will receive neoadjuvant and concurrent and adjuvant hormonal therapy
will be eligible.

- Willing to come to MSK Main Campus for baseline and follow-up MP-MRIs.

Exclusion Criteria:

- History of radical prostatectomy

- Patients who are unwilling or unable to undergo MRI including patients with
contraindications to MRI such as the presence of cardiac pacemakers or non-compatible
intracranial vascular clips, claustrophobia, inability to lie flat for the duration of
the study etc.

- Patients with a metallic hip implant, metallic implant or device in the pelvis or
ferromagnetic fiducial beacons (Calypso) that might distort local magnetic field and
compromise quality of MP-MRI

- Patients in which gadolinium contrast is contra-indicated.

- Metastatic disease